person · Reporting owner

Schneider Jennifer

Disclosed activity across 4 companies

Tapewire entity: 14717
SEC CIK: 0001783060

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Health Assurance Acquisition Corp.HAAC · Entity 122106	Director	November 12, 2020	November 13, 2020
Revolution Healthcare Acquisition Corp.REVH · Entity 135631	Director	March 17, 2021	March 17, 2021
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	Director	May 01, 2026	May 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Health Assurance Acquisition Corp.

Report date November 12, 2020 · Filed November 13, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B common stockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-11-12 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249667), as amended, under the heading "Description of Securities-Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the issuer after the consummation of the issuer's initial business combination.

Revolution Healthcare Acquisition Corp.

Report date March 17, 2021 · Filed March 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B common stockSEC Table I · non-derivative	Direct	6,250	Reported balance Holding disclosure · report date 2021-03-17 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 6,250 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.

VERTEX PHARMACEUTICALS INC / MA

Report date May 01, 2026 · Filed May 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,394	Ending reported balance After 2026-05-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-01 · Grant · Acquired 472 · Balance 2,190 F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Row 2 · 2026-05-01 · Disposition to issuer · Disposed 796 · Balance 1,394 F2: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $424.45 · Expires 2036-04-30	Direct	1,433	Reported balance After 2026-05-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-01 · Grant · Acquired 1,433 · Balance 1,433 F3: Fully vested.
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	796	Reported balance After 2026-05-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-01 · Grant · Acquired 796 · Balance 796 F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death. F2: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

F2: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

F3: Fully vested.

F4: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Livongo Health, Inc.

Report date October 30, 2020 · Filed October 30, 2020

Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-10-30 transaction · row 1 1 source row Row 1 · 2020-10-30 · Disposition to issuer · Disposed 208,387 · Balance 0 F1: Includes 197,304 restricted stock units ("RSUs"). F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. F3: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F4: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2025-09-02	Direct	Reported balance After 2020-10-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-30 · Disposition to issuer · Disposed 524,602 · Balance 0 F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F6: Shares subject to the option are fully vested and immediately exercisable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2026-11-15	Direct	Reported balance After 2020-10-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-30 · Disposition to issuer · Disposed 80,000 · Balance 0 F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F8: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2028-06-18	Direct	Reported balance After 2020-10-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-30 · Disposition to issuer · Disposed 150,000 · Balance 0 F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 197,304 restricted stock units ("RSUs").

F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.

F3: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).

F4: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).

F5: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.

F6: Shares subject to the option are fully vested and immediately exercisable.

F7: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions).

F8: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter.

F9: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 01, 2026 Filed May 5, 2026 21:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	796	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-26-000189 · wk-form4_1778016579.xml · derivative · entry 4 Schneider Jennifer · CIK 0001783060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 796 Underlying: Common Stock · 796 shares Expires not disclosed F4 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. F4 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death. F4 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death. Read SEC document
May 01, 2026 Filed May 5, 2026 21:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option (Right to Buy) · Derivative	1,433	$0.00 Strike: $424.45	$0.00	Disclosure SEC source: 0000875320-26-000189 · wk-form4_1778016579.xml · derivative · entry 3 Schneider Jennifer · CIK 0001783060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,433 Underlying: Common Stock · 1,433 shares Expires 2036-04-30 F3 · derivative.exercise_date: Fully vested. Read SEC document
May 01, 2026 Filed May 5, 2026 21:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Disposition to issuerCommon Stock	796	Not disclosed	Not disclosed	Disclosure SEC source: 0000875320-26-000189 · wk-form4_1778016579.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,394 F2 · price: Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document
May 01, 2026 Filed May 5, 2026 21:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	472	$0.00	$0.00	Disclosure SEC source: 0000875320-26-000189 · wk-form4_1778016579.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,190 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document
May 01, 2025 Filed May 5, 2025 20:57 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	796	$0.00	$0.00	Disclosure SEC source: 0000875320-25-000186 · wk-form4_1746478668.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,718 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document
May 15, 2024 Filed May 17, 2024 20:18 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	922	$0.00	$0.00	Disclosure SEC source: 0000875320-24-000148 · wk-form4_1715977097.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 922 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:19 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	150,000	Not disclosed Strike: $3.62	Not disclosed	Disclosure SEC source: 0001639225-20-000062 · wf-form4_160409272596424.xml · derivative · entry 4 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2028-06-18 F5 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F9 · derivative.exercise_date: One-fourth of the shares subject to the option vested on June 19, 2019 and 1/48 of the shares vest monthly thereafter. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:19 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	80,000	Not disclosed Strike: $1.38	Not disclosed	Disclosure SEC source: 0001639225-20-000062 · wf-form4_160409272596424.xml · derivative · entry 3 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2026-11-15 F5 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F8 · derivative.exercise_date: One-fourth of the shares subject to the option vested on November 16, 2017 and 1/48 of the shares vest monthly thereafter. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:19 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	524,602	Not disclosed Strike: $0.80	Not disclosed	Disclosure SEC source: 0001639225-20-000062 · wf-form4_160409272596424.xml · derivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 524,602 shares Expires 2025-09-02 F5 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7 · price: Pursuant to the Merger Agreement, each outstanding stock option of the Issuer, whether vested or unvested, was converted into an option to purchase a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such Issuer stock option immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), with an exercise price equal to the quotient of (x) the exercise price of such Issuer stock option and (y) the Equity Award Adjustment Ratio (rounded up to the nearest whole cent), subject to the same terms and conditions as were applicable to such Issuer stock option immediately prior to the effective time of the merger (including applicable vesting conditions). F6 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:19 UTC	Livongo Health, Inc. LVGO · Entity 145566	Disposition to issuerCommon Stock	208,387	Not disclosed	Not disclosed	Disclosure SEC source: 0001639225-20-000062 · wf-form4_160409272596424.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 197,304 restricted stock units ("RSUs"). F2 · shares: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. F3 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F4 · price: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F5 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. Read SEC document
September 03, 2020 Filed Sep 5, 2020 01:07 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	60,266	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-049679 · doc4.xml · derivative · entry 3 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,602 Underlying: Common Stock · 60,266 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document
September 03, 2020 Filed Sep 5, 2020 01:07 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	60,266	$124.50	$7,503,117.00	Disclosure SEC source: 0001209191-20-049679 · doc4.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,177 F1 · kind: On August 5, 2020, the Issuer entered into an Agreement and Plan of Merger with Teladoc Health, Inc. ("Teladoc") and Tempranillo Merger Sub, Inc., a wholly-owned subsidiary of Teladoc ("Merger Sub"), pursuant to which Merger Sub will merge with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Teladoc (the "Merger"). Pursuant to the terms of the Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019 (the "Trading Plan"), all sales pursuant to the Trading Plan were automatically suspended following the public announcement of the Merger without any action by the reporting person, and the Trading Plan was subsequently terminated. The majority of shares sold and reported on this form are consistent with the number of shares that would have been sold by the reporting person pursuant to the Trading Plan had the Trading Plan not been suspended in connection with the Merger. F2 · kind: Following the sales reported on this form, the reporting person continues to hold over 85% of the shares of the Issuer's common stock and vested stock options held immediately prior to such sales. Read SEC document
September 03, 2020 Filed Sep 5, 2020 01:07 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	60,266	$0.80	$48,212.80	Disclosure SEC source: 0001209191-20-049679 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 26, 2020 Filed Aug 28, 2020 20:13 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	8,598	$132.53	$1,139,492.94	Disclosure SEC source: 0001209191-20-048617 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,177 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 446 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on May 15, 2020. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	6,700	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · derivative · entry 18 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,868 Underlying: Common Stock · 6,700 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F14 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	100	$147.32	$14,732.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 16 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,329 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	800	$146.50	$117,198.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 15 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,429 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.07 to $146.99, inclusive. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	100	$144.66	$14,466.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 14 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,229 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	400	$143.62	$57,448.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 13 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,329 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.50 to $143.90, inclusive. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	900	$142.37	$128,136.96	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 12 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.145 to $142.74, inclusive. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	1,700	$141.54	$240,610.52	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 11 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,629 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.105 to $141.72, inclusive. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	1,400	$140.48	$196,670.04	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 10 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,329 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.11 to $140.97, inclusive. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	900	$139.78	$125,799.48	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 9 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.405 to $139.98, inclusive. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	400	$138.74	$55,497.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 8 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,629 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.72 to $138.81, inclusive. Read SEC document
August 04, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	6,700	$0.80	$5,360.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 7 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	6,700	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · derivative · entry 17 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,568 Underlying: Common Stock · 6,700 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F14 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	303	$133.24	$40,370.96	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 6 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,329 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.025 to $133.64, inclusive. Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	600	$132.54	$79,523.52	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 5 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,632 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.06 to $132.715, inclusive. Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	3,397	$131.41	$446,385.16	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 4 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,232 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.02 to $131.85, inclusive. Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	1,600	$130.56	$208,891.04	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 3 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,629 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.24 to $130.90, inclusive. Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	800	$129.73	$103,780.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,229 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.00 to $129.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (13) to this Form 4. Read SEC document
August 03, 2020 Filed Aug 5, 2020 20:25 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	6,700	$0.80	$5,360.00	Disclosure SEC source: 0001209191-20-045106 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
July 02, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	6,700	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · derivative · entry 9 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,268 Underlying: Common Stock · 6,700 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F7 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document
July 02, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	3,639	$74.59	$271,439.56	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · nonDerivative · entry 7 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,329 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.18 to $74.81, inclusive. Read SEC document
July 02, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	3,061	$73.57	$225,208.79	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · nonDerivative · entry 6 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,968 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.93, inclusive. Read SEC document
July 02, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	6,700	$0.80	$5,360.00	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · nonDerivative · entry 5 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	5,124	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · derivative · entry 8 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,968 Underlying: Common Stock · 5,124 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F7 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	278	$76.04	$21,140.23	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · nonDerivative · entry 4 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,329 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.98 to $76.08, inclusive. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	2,800	$75.31	$210,863.52	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · nonDerivative · entry 3 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,607 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.85 to $75.50, inclusive. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	3,622	$73.71	$266,975.45	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,407 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.34 to $74.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:52 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	5,124	$0.80	$4,099.20	Disclosure SEC source: 0001209191-20-041046 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
June 02, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,816	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · derivative · entry 8 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,092 Underlying: Common Stock · 1,816 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F6 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document
June 02, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	6,700	$58.27	$390,378.18	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · nonDerivative · entry 6 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,905 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.99 to $58.60, inclusive. Read SEC document
June 02, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	1,816	$0.80	$1,452.80	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · nonDerivative · entry 5 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	6,175	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · derivative · entry 7 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,908 Underlying: Common Stock · 6,175 shares Expires 2025-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F6 · derivative.exercise_date: One-fourth of the shares subject to the option vested on September 1, 2016 and 1/48 of the shares vest monthly thereafter. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	1,908	$59.61	$113,728.25	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · nonDerivative · entry 4 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,789 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.40 to 60.00, inclusive. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	3,592	$59.02	$212,009.18	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · nonDerivative · entry 3 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,697 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.38 to $59.37, inclusive. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	SaleCommon Stock	1,200	$57.84	$69,407.04	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · nonDerivative · entry 2 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,289 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.34 to $58.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:46 UTC	Livongo Health, Inc. LVGO · Entity 145566	Exercise / conversionCommon Stock	6,175	$0.80	$4,940.00	Disclosure SEC source: 0001209191-20-034070 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2019. Read SEC document
May 26, 2020 Filed May 28, 2020 21:55 UTC	Livongo Health, Inc. LVGO · Entity 145566	Tax withholdingCommon Stock	6,354	$55.00	$349,470.00	Disclosure SEC source: 0001209191-20-032691 · doc4.xml · nonDerivative · entry 1 Schneider Jennifer · CIK 0001783060 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,314 F1 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.